The Potential Role of Simeprevir for the Treatment of Hepatitis C

Cristina del Barrio Gascón; Maria Buti


Future Virology. 2015;10(2):67-75. 

In This Article


SMV (Olysio) is a direct antiviral agent that blocks the action of the NS3/4A serine protease in the HCV, which is essential for the virus to multiply. SMV has been shown to be effective against HCV genotypes 1, 2, 4, 5 and 6. It is used to treat chronic hepatitis C infection in adults in combination with other medicines.

SMV has been investigated in three main studies involving 1178 patients with HCV genotype 1 infection in combination with PEG-IFN/RBV. All the studies have shown higher SVR rates that the combination of PEG-IFN/RBV. In addition, in a Phase II study, the combination of SMV and sofosbuvir in an IFN-free regimen also offer very promising results.